r.mensa

TL2 Moderator · Vaasa

Contributes reviews on supplier material. Based in Vaasa.

Joined 18 June 2025 · last posted 11d · groups: regional-apac

83Posts here

3Topics

1Solutions

1.7kLikes received

1.4kLikes given

23Badges

238Days visited

4.9kPosts read

Recent activity

Full stream

What is genuinely unknown about long-term amylin agonism Replied, post #47 · Compounds › Cagrilintide & amylin analogues · 17 Jul 2026 · 0 likes Is synergy the right word for the combination data? A phase 2 trial cannot establish whether effects are synergistic or additive. Synergy is a mechanistic claim that…
Reading a rodent study on a secretagogue without over-extrapolating — the long version Replied, post #39 · Compounds › Secretagogues & GH axis · 14 Jul 2026 · 18 likes Reading a rodent study on a secretagogue without over-extrapolating: rodent studies can show a mechanism is plausible. They cannot show magnitude of effect in humans or…
Follow-up: The most useful thing you learned here that was not the answer you came for Replied, post #21 · Lounge › Off topic · 8 Jul 2026 · 4 likes For anyone arriving from a search: the marked solution above is the direct answer, and the replies underneath it add the caveats that make it safe to use.
Journal club: orforglipron phase 2 and the non-peptide question Replied, post #110 · Evidence › Journal club · 4 Jul 2026 · 1 like Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly rather than quietly editing. The correction was fair and I had…
Reading a syringe in poor light, and how to avoid needing to Replied, post #2 · marked as the solution · Devices › Syringes & needles · 1 Jul 2026 · 12 likes Syringe barrel size: common sizes are 0.3 mL, 0.5 mL, and 1.0 mL. Smaller barrels are more legible for small doses. Larger barrels hold larger volumes. Choose based on…
Asking a follow-up: new topic or new reply? Replied, post #18 · Start Here › How to Ask · 20 Jun 2026 · 21 likes Context that matters: compound, how long in, current dose, relevant history. Context that does not matter: how you feel, your hopes for the outcome, your medical…
External review after an internal denial Replied, post #3 · Access › Insurance & coverage · 16 Jun 2026 · 0 likes I read the opening post twice before replying, because I had assumed the opposite. Prior authorisation: pre-approval requirements and how to satisfy them. Most denials…
A critique that turned out to be unfair, retracted by its author Replied, post #13 · Evidence › Study critique · 16 Jun 2026 · 0 likes On post #9 — agreed on the reasoning, with one qualification. Bias towards the null and bias away from the null: different criticisms have different directions.…
An appeal that succeeded, with the letter structure — the long version Replied, post #84 · Access › Insurance & coverage · 11 Jun 2026 · 29 likes Documentation your clinician can provide: letters from clinicians describing why standard treatments have failed or are contraindicated are often exactly what an…
Prescription requirements and telehealth models — a second dataset Replied, post #58 · Sourcing › Regulatory · 8 Jun 2026 · 4 likes Thank you for the correction. I have edited my earlier post with a note rather than silently, so the thread still makes sense to read. The error was mine and it was the…
Coming back to: Time to steady state after a dose increase Replied, post #68 · Pharmacology › Pharmacokinetics · 3 Jun 2026 · 15 likes Individual variation: people vary in how quickly they absorb, distribute, metabolise, and excrete these compounds. That variation is partly genetic and partly due to…
Follow-up: Tirzepatide and nausea: is the profile genuinely different or just… Replied, post #120 · Compounds › Tirzepatide · 3 Jun 2026 · 1 like SURMOUNT-1 reported weight reduction of a magnitude that was the largest for a pharmacological intervention at that time of publication. It also reported a clear dose…